The life sciences landscape in greater Kendall Square and MA has changed dramatically in the last decade. With the arrival of big pharma R&D centers starting with Novartis in 2002, the explosion of incubators across MA, and the migration of technology and digital media companies to Cambridge and Boston, we have seen profound and sweeping changes. From accelerating rents to massive new construction projects housing campuses for big pharma R&D, nowhere has this change been more profound than in Cambridge, and the face and fate of Kendall Square has and continues to evolve rapidly. What do these seismic evolutions augur for our future?

We will tackle such questions as:

• What opportunities & challenges will this provide for employees, investors and our new pharma partners?
• How will this affect the culture of our ecosystem and will it make the epicenter of the supercluster less livable?
• Will the cost of rents and real estate price emerging biotechs and their young workforce out of the area?
• How will this impact investor deployment of capital and investor returns?
• What additional demands will this place on our already stressed infrastructure and transportation systems?

Come join us for a glimpse into the future of Kendall Square and learn how these changes may impact biotech companies and their stakeholders in Cambridge and the surrounding areas.
Speakers:

• Peter Abair, Director, Economic Development & Global Affairs, MassBio
• Steven Gullans, PhD, Managing Director, Excel Medical Ventures, and author of Evolving Ourselves
• Brad Rosenblum,  Chief Financial & Administrative Officer, Massachusetts Life Sciences Center (MLSC)
• Jeffrey D. Wager, MD, Chairman & CEO, EnBiotix, Inc.

Moderators:

• Marc R. Cote, Chief Operating Officer and Co-founder, Accellient Partners, LLC
• John Hession, Partner,  Morse, Barnes-Brown & Pendleton, PC